Author

Andrew R. Allen

Observed names: A Allen, A. Allen, A.R. Allen, Andrew Allen, Andrew R Allen

Observed institutions: Biogen (United States), Virginia Mason Medical Center, Vanderbilt University, Hammersmith Hospital, Edinburgh Royal Infirmary, Abbott (United States), National Cancer Institute, Clovis Oncology (United States), Clovis Oncology (United Kingdom), Rutgers Cancer Institute, Imperial College London, Fundação Oswaldo Cruz, University of Glasgow, Vanderbilt University Medical Center, University of Edinburgh

OpenAlex ID: A5065505740

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

2016 · Elizabeth M Swisher, Kevin K Lin, et al. · The Lancet Oncology · 1,196

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

2015 · Lecia V. Sequist, Jean-Charles Soria, et al. · New England Journal of Medicine · 662

PDF

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

2013 · Annette O. Walter, Robert Tjin Tham Sjin, et al. · Cancer Discovery · 617

Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

2015 · Zofia Piotrowska, Matthew J. Niederst, et al. · Cancer Discovery · 459

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

2016 · Chris Karlovich, Jonathan W. Goldman, et al. · Clinical Cancer Research · 179

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

2014 · J.-C. Soria, F. DeBraud, et al. · Annals of Oncology · 174

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

2013 · Elizabeth Poplin, Harpreet Wasan, et al. · Journal of Clinical Oncology · 160

PDF

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

2014 · Lecia V. Sequist, Jean-Charles Soria, et al. · Journal of Clinical Oncology · 143

Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis.

1998 · A Allen, C Pusey, et al. · Journal of the American Society of Nephrology · 110

Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

2015 · Iain A. McNeish, Amit M. Oza, et al. · Journal of Clinical Oncology · 92

Translational Crossroads for Biomarkers

2005 · Robert C. Bast, Hans Lilja, et al. · Clinical Cancer Research · 83

Retransplantation in Alport post-transplant anti-GBM disease

2004 · Gemma Browne, Paul A.J. Brown, et al. · Kidney International · 70

In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

2014 · Robert Tjin Tham Sjin, Kwangho Lee, et al. · Molecular Cancer Therapeutics · 68

Endothelial Expression of VCAM-1 in Experimental Crescentic Nephritis and Effect of Antibodies to Very Late Antigen-4 or VCAM-1 on Glomerular Injury

1999 · Andrew R Allen, Julie McHale, et al. · The Journal of Immunology · 45

PDF

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.

2013 · Lecia V. Sequist, Jean-Charles Soria, et al. · Journal of Clinical Oncology · 42

Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis

2004 · John Reynolds, Sarah B. Khan, et al. · Kidney International · 42

PDF

Treatment with an Antibody to VLA-1 Integrin Reduces Glomerular and Tubulointerstitial Scarring in a Rat Model of Crescentic Glomerulonephritis

2002 · H. Terence Cook, Sarah B. Khan, et al. · American Journal Of Pathology · 37

PDF

A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.

2013 · Rebecca Sophie Kristeleit, Geoffrey Shapiro, et al. · Journal of Clinical Oncology · 24

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression

2014 · D. Li, S. Pant, et al. · Pancreatology · 21

VCAM-1 has a tissue-specific role in mediating interleukin-4–induced eosinophil accumulation in rat models: evidence for a dissociation between endothelial-cell VCAM-1 expression and a functional role in eosinophil migration

2000 · Karen Y. Larbi, Andrew R. Allen, et al. · Blood · 21

A phase I study of oral rucaparib in combination with carboplatin.

2013 · L Rhoda Molife, Patricia Roxburgh, et al. · Journal of Clinical Oncology · 18

Selective renal transplantation in primary hyperoxaluria type 1

1996 · A.R. Allen, E.M. Thompson, et al. · American Journal of Kidney Diseases · 18

2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib

2015 · K. Lin, J. Sun, et al. · European Journal of Cancer · 15

Abstract 793: Insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR) inhibitory activity of rociletinib (CO-1686) and its metabolites in nonclinical models

2015 · Andrew D. Simmons, Sarah Jaw-Tsai, et al. · Cancer Research · 14

Blocking VLA-4 Prevents Progression of Experimental Crescentic Glomerulonephritis

2003 · Sarah B. Khan, Andrew R. Allen, et al. · Nephron Experimental Nephrology · 14

Works count: 66

Citation count: 4,470

H-index: 20

I10-index: 33